AG
CRNX icon

Aperio Group’s Crinetics Pharmaceuticals CRNX Stock Holding History

Aperio Group’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-10,910
Closed -$171K – 2434
2020
Q3 		$171K Buy
+10,910
New +$167K ﹤0.01% 2256

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Aperio Group's CRNX Position: Q4 2020 in Review

Aperio Group sold out of Crinetics Pharmaceuticals (CRNX) in Q4 2020, closing a stake of 10,910 shares — an estimated $171K sold.

Aperio Group first reported a position in CRNX in Q3 2020 and held it in 1 quarter. The position peaked at $171K in Q3 2020. 85 funds tracked by Wall St. Rank hold CRNX as of Q4 2020.

  • Aperio Group reported no remaining Crinetics Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Aperio Group sold 10,910 Crinetics Pharmaceuticals shares in Q4 2020, an estimated $171K.
  • Aperio Group first reported a position in Crinetics Pharmaceuticals in Q3 2020 and held it in 1 quarter.
  • Aperio Group's Crinetics Pharmaceuticals position peaked at $171K in Q3 2020.
  • 85 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.